SOBIN-AD
Alzheimer's Disease
PreclinicalActive
Key Facts
About AltPep
AltPep is pioneering a novel approach to amyloid diseases by targeting the toxic soluble oligomers that form early in disease progression, rather than the later-stage plaques. Founded in 2018 on decades of academic research from the University of Washington, the company has built a dual-purpose platform for both diagnostics (SOBA) and therapeutics (SOBIN). Its lead programs are in preclinical development for Alzheimer's and Parkinson's diseases, aiming to enable pre-symptomatic intervention in a market affecting over a billion people globally. The company is led by its founder and CEO, Dr. Valerie Daggett, who discovered the foundational α-sheet structure.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |